SOAT1 and Alzheimer disease: Knowledge about the action of cytokines through their specific cell receptors and the existence of the JAK-STAT intracellular signaling system in AD has led to the emergence of therapeutic strategies aimed at blocking cytokines or their extracellular receptors with monoclonal antibodies for subcutaneous use, and also the approach of partial interruption of the JAK-STAT system using drugs called small molecules for oral use, as shown in Fig. 5.